Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment.

ABSTRACT:

Background

Cancer immunotherapy includes vaccines generated through distinct approaches, each with advantages and limitations. Those made of autologous or allogeneic whole cells do not require prior identification of antigens, that is, immunize against undetermined (agnostic) tumor antigens. However, they often exhibit low adjuvanticity and modest antigenicity. Viruses have emerged as elicitors and enhancers of immune responses. Oncolytic viruses are replicating anticancer agents, most often administered intratumorally. They derepress the immunosuppressive tumor microenvironment through different mechanisms, and some promote antitumor immunity-a strategy termed oncolytic immunotherapy. Tropism-retargeted oncolytic herpes simplex viruses (here ReHVs), generated in our laboratory, sp

SUBMITTER: Vannini A 

PROVIDER: S-EPMC12306237 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature